<?xml version="1.0" encoding="UTF-8"?>
<p>Alzheimerâ€™s Disease (AD) is a neurodegenerative disease which is the common cause of dementia and is mainly differentiated by progressive deterioration of memory and cognition [
 <xref rid="B1-molecules-25-03353" ref-type="bibr">1</xref>]. It is characterized by low levels of the neurotransmitter acetylcholine (ACh), neuro-inflammation, and oxidative stress in the brain region [
 <xref rid="B2-molecules-25-03353" ref-type="bibr">2</xref>]. There are millions of people worldwide with AD and dementia and the World Health Organization (WHO) estimates the number of people with AD is rising rapidly [
 <xref rid="B3-molecules-25-03353" ref-type="bibr">3</xref>]. Nowadays, about 24 million of peoples are affected by AD and it is predicted that this number will quadruple by 2050 [
 <xref rid="B4-molecules-25-03353" ref-type="bibr">4</xref>]. Previous studies performed on AD patients found an altered cholinergic activity, which resulted in disruption cognitive and functional symptoms [
 <xref rid="B5-molecules-25-03353" ref-type="bibr">5</xref>]. AD is reported to affect older people of 65 years old and above, resulting in memory and behavior impairment [
 <xref rid="B6-molecules-25-03353" ref-type="bibr">6</xref>]. One of the most promising targets for AD treatment is by suppressing the acetylcholinesterase (AChE) activity in the brain to ameliorate the cognitive ability [
 <xref rid="B7-molecules-25-03353" ref-type="bibr">7</xref>].
</p>
